Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced a symposium on sotagliflozin during the American Diabetes Association’s 81st Scientific Sessions from June 25-29, 2021. The event will focus on updates from the SCORED and SOLOIST cardiovascular and kidney outcomes trials on June 29. Sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, is approved in the EU for adults with type 1 diabetes who struggle with glycemic control despite optimal insulin therapy, yet has not been commercially launched. This highlights Lexicon's commitment to advancing diabetes treatment.
- Sotagliflozin has received EU approval for use alongside insulin therapy.
- The upcoming symposium showcases ongoing research and potential future developments in diabetes treatment.
- Sotagliflozin has not yet been commercially launched despite EU approval.
- There are risks and uncertainties regarding the successful clinical development and regulatory approvals of drug candidates.
THE WOODLANDS, Texas, June 25, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Association’s 81st Scientific Sessions being held virtually June 25, 2021 through June 29, 2021:
- Tuesday, June 29, 2021, 10:15 am – 12:15 pm ET; entitled “Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials”
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211, sotagliflozin and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Inquiries:
Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com
FAQ
What is the significance of Lexicon Pharmaceuticals' upcoming symposium on June 29, 2021?
What is sotagliflozin and its current status?
How does sotagliflozin work?
What are the potential risks associated with Lexicon Pharmaceuticals?
What does the forward-looking statement in the press release indicate?
